A collaborative program involving the Peter Boris Centre for Addictions Research, the Michael G. DeGroote Centre for Medicinal Cannabis Research, and McMaster Continuing Education. Click for more information.
A new knowledge synthesis reviewing the safety profile of cannabidiol (CBD) for human consumption. Review was written by Vikas Parihar, PharmD; James MacKillop, PhD; and Jason W. Busse, DC, PhD.
Why was this study conducted? What does this study add? Is there anything else I should know?
Tibbo PG, McKee KA, Meyer JH, Crocker CE, Aitchison KJ, Lam RW, Crockford DN. Position Statement of the Canadian Psychiatric Association: Are there therapeutic benefits of cannabinoid products in adult mental illness? Can J Psychiatry 2020
“With the number of users registered with Health Canada up from about 8,000 in 2014 to nearly 235,000 people today there is an increased need to seek scientific evidence about the potential harms and benefits of medicinal cannabis.”
- Dr. James MacKillop, February 2018, Innovations in the Science of Medicinal Cannabis Conference